Equillium Stock Today
| EQ Stock | USD 1.55 0.14 9.93% |
PerformanceGood
| Odds Of DistressSmall
|
Equillium is selling at 1.55 as of the 3rd of November 2025; that is 9.93 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.38. Equillium has about a 34 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 4th of October 2025 and ending today, the 3rd of November 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2018 | Category Healthcare | Classification Health Care |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. The company has 59.5 M outstanding shares of which 779.64 K shares are currently sold short in the market by investors with about 1.11 days to cover all shorted shares. More on Equillium
Moving against Equillium Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Equillium Stock Highlights
| Chairman of the Board, CEO | Daniel Bradbury | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEquillium can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Equillium's financial leverage. It provides some insight into what part of Equillium's total assets is financed by creditors.
| |||||
Equillium (EQ) is traded on NASDAQ Exchange in USA and employs 35 people. Equillium is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a market capitalization of 92.23 M. Equillium is active under Biotechnology sector as part of Health Care industry. The entity has 59.5 M outstanding shares of which 779.64 K shares are currently sold short in the market by investors with about 1.11 days to cover all shorted shares.
Equillium reports about 57.56 M in cash with (19.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Equillium Probability Of Bankruptcy
Ownership AllocationEquillium holds a total of 59.5 Million outstanding shares. Equillium retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Equillium Ownership Details
Equillium Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Prudential Financial Inc | 2025-06-30 | 39.2 K | |
| Northern Trust Corp | 2025-06-30 | 35 K | |
| Commonwealth Equity Services Inc | 2025-06-30 | 25 K | |
| Baader Bank Inc | 2025-06-30 | 23.7 K | |
| Ground Swell Capital, Llc | 2025-06-30 | 16.6 K | |
| Susquehanna International Group, Llp | 2025-06-30 | 15.1 K | |
| Apollon Wealth Management, Llc | 2025-06-30 | 13.9 K | |
| Tritonpoint Wealth Llc | 2025-06-30 | 13.5 K | |
| Virtu Financial Llc | 2025-06-30 | 10.2 K | |
| Decheng Capital Llc | 2025-06-30 | 4.4 M | |
| Takeda Pharmaceutical Co Ltd | 2025-06-30 | 1.8 M |
Equillium Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Equillium market risk premium is the additional return an investor will receive from holding Equillium long position in a well-diversified portfolio.
| Mean Deviation | 7.57 | |||
| Semi Deviation | 5.69 | |||
| Standard Deviation | 12.91 | |||
| Variance | 166.55 |
Equillium Stock Against Markets
Equillium Corporate Management
| Jason Keyes | Chief Officer | Profile | |
| Matthew Ritter | Senior Development | Profile | |
| Penny Tom | Principal Officer | Profile | |
| Maple MD | Chief Officer | Profile | |
| Krishna MD | Consultant | Profile | |
| Lisette Acevedo | Vice Development | Profile |
Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.